Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.54 |
| ▸ | CTSD | P07339 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diphenylacetic Acid SCHEMBL8513250 | 0.78 | SRC (0.62) | TDP1L3MBTL1HDAC3HDAC4HDAC1 | |
| Diphenylacetic Acid SCHEMBL38022 | 0.78 | SRC (0.62) | TDP1L3MBTL1HDAC3HDAC4HDAC1 | |
| SCHEMBL465969 | 0.78 | TDP1 (0.61) | TDP1L3MBTL1HDAC3HDAC4HDAC1 | |
| SCHEMBL3728852 | 0.77 | LMNA (0.65) | TDP1L3MBTL1HDAC3HDAC4HDAC1 | |
| SCHEMBL11223553 | 0.77 | SRC (0.48) | TDP1L3MBTL1HDAC3HDAC4HDAC1 | |
| SCHEMBL4849143 | 0.77 | LMNA (0.65) | TDP1L3MBTL1HDAC3HDAC4HDAC1 | |
| SCHEMBL4850637 | 0.77 | LMNA (0.65) | TDP1L3MBTL1HDAC3HDAC4HDAC1 | |
| SCHEMBL7450800 | 0.77 | TDP1 (0.43) | TDP1L3MBTL1HDAC3HDAC4HDAC1 | |
| Diphenylacetic Acid SCHEMBL6852183 | 0.76 | SRC (0.59) | TDP1L3MBTL1HDAC3HDAC4HDAC1 | |
| Diphenylacetic Acid SCHEMBL8411440 | 0.76 | SRC (0.59) | TDP1L3MBTL1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337536-B1 | CATIONIC GROUP-3 CATALYST SYSTEM | EXXONMOBIL CHEM PATENTS INC (US) | 2012-09-12 | — | — | EP | claimed |
| JP-4838934-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| US-7390861-B2 | Cationic group-3 catalyst system | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2008-06-24 | — | — | US | claimed |
| EP-1044197-B1 | PIPERIDINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKYNE CARBOXAMIDES AS CYTOSTATIC AGENTS AND IMMUNOSUPPRESSANTS | ASTELLAS PHARMA GMBH (DE) | 2006-04-19 | — | — | EP | claimed |
| EP-1042291-B1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2005-07-13 | — | — | EP | claimed |
| EP-1515997-A1 | YTTRIUM-BASED ETHYLENE POLYMERIZATION CATALYSTS WITH BULKY AMIDINATE ANCILLARY LIGANDS | ExxonMobil Chemical Patents Inc. (US) | 2005-03-23 | — | — | EP | claimed |
| US-20040033889-A1 | Yttrium-based ethylene polymerization catalysts with bulky amidinate ancillary ligands | EXXONMOBIL CHEMICAL PATENTS INC. | 2004-02-19 | — | — | US | claimed |
| US-20040033891-A1 | Cationic group-3 catalyst system | EXXONMOBIL CHEMICAL PATENTS INC. | 2004-02-19 | — | — | US | claimed |
| WO-2004000894-A1 | YTTRIUM-BASED ETHYLENE POLYMERIZATION CATALYSTS WITH BULKY AMIDINATE ANCILLARY LIGANDS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2003-12-31 | — | — | WO | claimed |
| EP-1337536-A1 | CATIONIC GROUP-3 CATALYST SYSTEM | ExxonMobil Chemical Patents Inc. (US) | 2003-08-27 | — | — | EP | claimed |
| US-6593344-B1 | These substances have especially high cytostatic activities and pronounced immunosuppressive properties which make them suitable for therapeutic treatment in broad tumor spectrum and autoimmune diseases | KLINGE PHARMA GMBH (DE) | 2003-07-15 | — | — | US | claimed |
| WO-2002032909-A1 | CATIONIC GROUP-3 CATALYST SYSTEM | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2002-04-25 | — | — | WO | claimed |
| EP-1044197-A2 | NEW PIPERIDINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | Klinge Pharma GmbH (DE) | 2000-10-18 | — | — | EP | claimed |
| EP-1042291-A1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | Klinge Pharma GmbH (DE) | 2000-10-11 | — | — | EP | claimed |
| WO-1999031060-A2 | PIPERIDINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES AS CYTOSTATICS AND IMMUNESUPPRESSANTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | claimed |
| WO-1999031064-A1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | claimed |
| EP-0552489-B1 | Peptide, production and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-03-04 | — | — | EP | claimed |
| US-10077288-B2 | Hydroxystatin derivatives for the treatment of arthrosis | MERCK PATENT GMBH (DE) | 2018-09-18 | — | — | US | disclosed |
| US-4151300-A | CENTRAL NERVOUS SYSTEM, PSYCHOTROPIC | LABORATOIRE L. LAFON (FR) | 1979-04-24 | — | — | US | disclosed |
| US-4122186-A | PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1978-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077288-B2 | Hydroxystatin derivatives for the treatment of arthrosis | CTSD, CTSB, CTSZ | TDP1 1632/4885L3MBTL1 2640/4885HDAC3 766/4885 |
| US-20040033891-A1 | Cationic group-3 catalyst system | COG3, ORC3, LIG3 | TDP1 4378/4885L3MBTL1 489/4885HDAC3 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.